Company |
Partner |
Amt. |
Details |
Date |
TOTAL: $275M (YEAR TO DATE: $1,014M) | ||||
Ablynx NV (Ghent, Belgium) |
Novo Nordisk A/S (Bagsvaerd, Denmark) |
$1.10 |
For achieving an initial discovery milestone with a multispecific Nanobody construct as part of its collaboration with Novo Nordisk, triggering a €1M (US$1.1M) payment to Ablynx |
12/1/16 |
Achillion Pharmaceuticals Inc. (New Haven, Conn.) |
Janssen Research & Development LLC (unit of Johnson & Johnson; New Brunswick, N.J.) |
$15.00 |
Related to the enrollment in the OMEGA-1 phase IIb trial testing JNJ-4178 for treatment-naïve chronic hepatitis C virus infection without cirrhosis |
12/29/16 |
Bioatla LLC (San Diego) |
Beijing Sinobioway Group Co. Ltd. (Beijing, China) |
$36.00 |
For the selection of the first four CAB product programs for development; last year, Bioatla and Sinobioway entered into a strategic collaboration for the development and commercialization of select CAB antibodies for specific indications in China, Hong Kong, Macau and Taiwan |
12/7/16 |
Cytokinetics Inc. (South San Francisco) |
Amgen Inc. (Thousand Oaks, Calif.) |
$26.70 |
For activating the first clinical site and starting the GALACTIC-HF phase III cardiovascular outcomes trial of omecamtiv mecarbil |
12/2/16 |
Cytomx Therapeutics Inc. (South San Francisco) |
Bristol-Myers Squibb Co. (New York) |
$15.00 |
For selection of the fourth and final target under their strategic oncology collaboration established in 2014 |
12/6/16 |
Cytomx Therapeutics Inc. (South San Francisco) |
Bristol-Myers Squibb Co. (New York) |
$2.00 |
For selection of a clinical candidate for its CTLA-4 Probody program under the companies' strategic oncology collaboration established in May 2014 |
12/14/16 |
Galapagos NV (Mechelen, Belgium) |
Gilead Sciences Inc. (Foster City, Calif.) |
$10.00 |
For the first dosing of a patient in the SELECTION phase IIb/III study with Janus kinase 1 inhibitor filgotinib in ulcerative colitis |
12/12/16 |
Genmab A/S (Copenhagen) |
Janssen Pharmaceutica KK (part of Johnson & Johnson; New Brunswick, N.J.) |
$10.00 |
For the submission of a new drug application to Japan's Ministry of Health, Labor and Welfare, seeking permission to market Darzalex (daratumumab) for the treatment of adults with relapsed or refractory multiple myeloma |
12/21/16 |
Genticel SA (Toulouse, France) |
Serum Institute of India Pvt. Ltd. |
$1.20 |
As per the agreement signed in February 2015 with Genticel, Serum Institute has been evaluating the benefits of using GTL003 in new and improved multivalent vaccines and has obtained excellent preclinical results |
12/1/16 |
Ionis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Astrazeneca plc (London) |
$28.00 |
For Astrazeneca's completion of investigational new drug application-supporting studies and license of IONIS-KRAS-2.5Rx, or AZD4785, an investigational medicine directly targeting KRAS |
12/19/16 |
Ionis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Astrazeneca plc (London) |
$25.00 |
For moving its lead candidate, newly renamed AZD8233, into preclinical development; the antisense drug, a potential treatment for cardiovascular disease, previously was called IONIS-AZ4-2.5-LRx |
12/21/16 |
Ionis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$5.00 |
For the validation of an undisclosed target to treat patients with a gastrointestinal autoimmune disease |
12/23/16 |
Ionis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Biogen Inc. (Cambridge, Mass.) |
$60.00 |
For the FDA approval of Spinraza for spinal muscular atrophy |
12/28/16 |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) |
Astellas Pharma Inc. (Tokyo) |
$15.00 |
For marketing approval from the Japanese Ministry of Health, Labor and Welfare for Linzess (linaclotide) as the first prescription treatment for adults with irritable bowel syndrome with constipation in Japan |
12/20/16 |
Myokardia Inc. (South San Francisco) |
Sanofi SA (Paris) |
$25.00 |
In conjunction with the filing of an investigational new drug application with the FDA for MYK-491 to treat dilated cardiomyopathy |
12/5/16 |
Polyphor Ltd. (Allschwil, Switzerland) |
Taisho Pharmaceutical Co. Ltd. (Tokyo) |
ND |
As part of their collaboration to identify drug candidates using Polyphor's proprietary macrocycle platform; compounds resulting from the collaboration have shown positive activity in key animal disease models in a core research area of Taisho, which has resulted in an undisclosed milestone payment to Polyphor |
12/13/16 |
Vernalis plc (Winnersh, U.K.) |
Tris Pharma Inc. (Monmouth Junction, N.J.) |
ND |
For the FDA accepting the CCP-08 NDA for full review; the FDA set a PDUFA date of Aug. 4, 2017; CCP-08 is the third product from Tris' extended-release cough/cold pipeline to be accepted for full NDA review |
12/23/16 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||